# Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy

> **NCT06375915** · PHASE2 · RECRUITING · sponsor: **Francesco De Cobelli** · enrollment: 33 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **RADIATION:** radioembolization with Y-90
- **DRUG:** Durvalumab
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06375915
- **Lead sponsor:** Francesco De Cobelli
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-05-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375915, "Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06375915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*